No Data
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Elevation Oncology Analyst Ratings
Buy Rating Affirmed for Elevation Oncology Amid Promising EO-3021 Phase 1 Results and Strategic Development Approach
Elevation Oncology Reports Data From Phase I Trial of EO-3021 for Solid Tumours
TD Cowen Maintains Elevation Oncology(ELEV.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Elevation Oncology(ELEV.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 17.7% over the